Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Drug Investigation
Published in: Clinical Drug Investigation 4/2015

01-04-2015 | Short Communication

Dosing Nucleoside Reverse Transcriptase Inhibitors in Adults Receiving Continuous Veno-Venous Hemofiltration

Authors: Milena M. McLaughlin, Abeer T. Ammar, Lana Gerzenshtein, Kimberly K. Scarsi

Published in: Clinical Drug Investigation | Issue 4/2015

Login to get access

Abstract

Background and Objective

Characteristics of nucleoside reverse transcriptase inhibitors (NRTIs) make the drug class susceptible to elimination via continuous veno-venous hemofiltration (CVVH), potentially leading to suboptimal drug concentrations if given at the recommended anephric doses during CVVH. The objective of this study was to formulate NRTI dosing recommendations for adults receiving CVVH.

Methods

A mathematical formula that estimates the amount of drug likely to be removed during CVVH at various flow rates was used to calculate the supplemental NRTI dose required during CVVH.

Results

A proposed table of dosing recommendations for NRTIs during CVVH is presented.

Conclusion

Clinicians should utilize these recommendations in the context of each individual patient, taking into consideration patient-specific factors and severity of illness. Future pharmacokinetic research correlating plasma and intracellular concentrations of NRTIs during CVVH is warranted to elucidate appropriate dosing.
Appendix
Available only for authorised users
Literature
1.
Palella FJ Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4 + cell strata. Ann Intern Med. 2003;138:620–6.CrossRefPubMed
2.
Calza L. Renal toxicity associated with antiretroviral therapy. HIV Clin Trials. 2012;13:189–211.CrossRefPubMed
3.
Forni LG, Hilton PJ. Continuous hemofiltration in the treatment of acute renal failure. N Engl J Med. 1997;336:1303–9.CrossRefPubMed
4.
Susla GM. The impact of continuous renal replacement therapy on drug therapy. Clin Pharmacol Ther. 2009;86:562–5.CrossRefPubMed
5.
O’Reilly P, Tolwani A. Renal replacement therapy III: IHD, CRRT, SLED. Crit Care Clin. 2005;21:367–78.CrossRefPubMed
6.
Golper TA, Marx MA. Drug dosing adjustments during continuous renal replacement therapies. Kidney Int Suppl. 1998;66:S165–8.PubMed
7.
Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005;41:1159–66.CrossRefPubMed
8.
Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically iii adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy. 2009;29:562–77.CrossRefPubMed
9.
Izzedine H, Launay-Vacher V, Baumelou A, Deray G. An appraisal of antiretroviral drugs in hemodialysis. Kidney Int. 2001;60:821–30.CrossRefPubMed
10.
Gupta SK, Eustace JA, Winston JA, Boydstun II, Ahuja TS, Rodriguez RA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559–85.CrossRefPubMed
11.
Fabbiani M, Di Giambenedetto S, Bracciale L, Bacarelli A, Ragazzoni E, Cauda R, et al. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. J Antimicrob Chemother. 2009;64:109–17.CrossRefPubMed
12.
Fletcher CV, Anderson PL, Kakuda TN, Schacker TW, Henry K, Gross CR, et al. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS. 2002;16:551–60.CrossRefPubMed
13.
Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003;36:1070–3.CrossRefPubMed
14.
15.
16.
McCabe SM, Ma Q, Slish JC, Catanzaro LM, Sheth N, DiCenzo R, et al. Antiretroviral therapy: pharmacokinetic considerations in patients with renal or hepatic impairment. Clin Pharmacokinet. 2008;47:153–72.CrossRefPubMed
17.
Reetze-Bonorden P, Bohler J, Keller E. Drug dosage in patients during continuous renal replacement therapy: pharmacokinetic and therapeutic considerations. Clin Pharmacokinet. 1993;24:362–79.CrossRefPubMed
18.
Smith BS, Yogaratnam D, Levasseur-Franklin KE, Forni A, Fong J. Introduction to drug pharmacokinetics in the critically ill patient. Chest. 2012;141:1327–36.CrossRefPubMed
19.
Fletcher CV, Kawle SP, Kakuda TN, Anderson PL, Weller D, Bushman LR, et al. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS. 2000;14:2137–44.CrossRefPubMed
20.
Kredo T, Van der Walt JS, Siegfried N, Cohen K. Therapeutic drug monitoring of antiretrovirals for people with HIV. Cochrane Database Syst Rev. 2009;(3):CD007268.
21.
Moore JD, Acosta EP, Johnson VA, Bassett R, Eron JJ, Fischl MA, et al. Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy. Antivir Ther. 2007;12:981–6.PubMed
22.
Taegtmeyer AB, Muller V, Kovari H, Kullak-Ublick GA, Corti N. Effect of continuous venovenous hemodiafiltration on darunavir and raltegravir exposure after administration via a gastroduodenal tube. AIDS. 2011;25:1339–41.CrossRefPubMed
23.
Didanosine (Videx) [package insert]. Princeton: Bristol-Meyers Squibb; 2004.
24.
Lambert JS, Seidlin M, Reichman RC, Plank CS, Laverty M, Morse GD, et al. 2’,3’-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med. 1990;322:1333–40.CrossRefPubMed
25.
Emtricitabine (Emtriva) [package insert]. Foster City: Gilead; 2011.
26.
Lamivudine (Epivir) [package insert]. Research Triangle Park: GlaxoSmithKline; 2008.
27.
Johnson MA, Verpooten GA, Daniel MJ, Plumb R, Moss J, Van Caesbroeck D, et al. Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis. Br J Clin Pharmacol. 1998;46:21–7.CrossRefPubMedCentralPubMed
28.
van Leeuwen R, Lange JM, Hussey EK, Donn KH, Hall ST, Harker AJ, et al. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS. 1992;6:1471–5.CrossRefPubMed
29.
Stavudine (Zerit) [package insert]. Princeton: Bristol-Meyers Squibb; 2010.
30.
Tenofovir (Viread) [package insert]. Foster City: Gilead; 2012.
31.
Zidovudine (Retrovir) [package insert]. Research Triangle Park: GlaxoSmithKline; 2012.
32.
Deray G, Diquet B, Martinez F, Vidal AM, Petitclerc T, Ben Hmida M, et al. Pharmacokinetics of zidovudine in a patient on maintenance hemodialysis. N Engl J Med. 1988;319:1606–7.CrossRefPubMed
33.
Paoli I, Dave M, Cohen BD. Pharmacodynamics of zidovudine in patients with end-stage renal disease. N Engl J Med. 1992;326:839–40.CrossRefPubMed
34.
Singlas E, Pioger JC, Taburet AM, Colin JN, Fillastre JP. Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis. Clin Pharmacol Ther. 1989;46:190–7.CrossRefPubMed
Metadata
Title
Dosing Nucleoside Reverse Transcriptase Inhibitors in Adults Receiving Continuous Veno-Venous Hemofiltration
Authors
Milena M. McLaughlin
Abeer T. Ammar
Lana Gerzenshtein
Kimberly K. Scarsi
Publication date
01-04-2015
Publisher
Springer International Publishing
Published in
Clinical Drug Investigation / Issue 4/2015
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.1007/s40261-015-0275-9

Other articles of this Issue 4/2015

Clinical Drug Investigation 4/2015 Go to the issue

Original Research Article

Dose-Exposure Proportionality of a Novel Recombinant Follicle-Stimulating Hormone (rFSH), FE 999049, Derived from a Human Cell Line, with Comparison Between Caucasian and Japanese Women After Subcutaneous Administration

Systematic Review

Incidence and Risk of Hypertension with Ramucirumab in Cancer Patients: A Meta-Analysis of Published Studies

Original Research Article

Effects of Ethanol on the Pharmacokinetics of Extended-Release Oxycodone with Sequestered Naltrexone (ALO-02)

Original Research Article

Efficacy of an Innovative Aerosol Foam Formulation of Fixed Combination Calcipotriol plus Betamethasone Dipropionate in Patients with Psoriasis Vulgaris

Original Research Article

Effect of Age and Sex on Lacosamide Pharmacokinetics in Healthy Adult Subjects and Adults with Focal Epilepsy

Original Research Article

Health Economic Evaluation of Paricalcitol® Versus Cincalcet + Calcitriol (Oral) in Italy